CureVac N.V.
Graf
Viktig: Aksjeinvesteringer kan over tid gi positiv avkastning, men innebærer risiko. Du kan tape deler av eller hele investeringen. Historisk avkastning for denne aksjen er ikke en pålitelig indikator på fremtidig avkastning. Data fra eksterne leverandører gjengis uendret av Saxo. Se fullstendig ansvarsfraskrivelse for data.
Om CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
/ 